
      <html>
        <head>
          <meta charset="UTF-8">
          <style>
            body {
              font-family: 'Georgia', serif;
              line-height: 1.6;
              padding: 2rem;
              color: #333;
            }
            h1, h2, h3 {
              color: #1a202c;
              border-bottom: 1px solid #ccc;
              padding-bottom: 0.2em;
              margin-top: 2rem;
            }
            ul {
              margin-left: 1.2rem;
              list-style-type: disc;
            }
            table {
              width: 100%;
              border-collapse: collapse;
              margin: 1rem 0;
            }
            th, td {
              border: 1px solid #999;
              padding: 0.5rem;
              text-align: left;
            }
            code, pre {
              font-family: monospace;
              background: #f5f5f5;
              padding: 0.3rem;
            }
          </style>
        </head>
        <body>
          <div class="content">
          ## Thyroid Nodule

### Benign Thyroid Nodules

### Thyroid Cancer

## Thyroid Nodule

### Prevalence

- Extraordinarily common
- Depends on:
    - Iodine deficiency
    - Ionizing radiation
    - Gender
    - Age
    - Method of detection (Palpation, Autopsy, or Ultrasound)

> Mazzaferri E, New Engl J Med 1993

## Thyroid Cancer

### Incidence, Mortality, and Stage

> McLeod DSA et al, Lancet 2013 & Davies et al., JAMA 2006


## Goiter

### Classification

- **Neoplastic Goiter:**
    - Benign
    - Malignant
- **Thyroiditis:**
    - Bacterial (acute suppurative)
    - Viral (subacute)
    - Lymphocytic/Hashimoto/Autoimmune (chronic)
- **Simple Goiter (endemic or sporadic):**
    - Diffuse
    - Nodular
- **Toxic Goiter:**
    - Diffuse toxic (Graves’)
    - Toxic nodular (Plummer’s)
    - Toxic/functioning adenoma


## Thyroid Nodule

### Pathology

- Nodular goiter: colloid / hemorrhagic cystic / complex / hyperplastic / adenomatous nodule (70%)
- Benign follicular adenoma: mainly non-toxic (15%)
- Well-differentiated thyroid carcinoma (10%)
- Miscellaneous: other thyroid malignancies, thyroiditis (5%)


## Thyroid Nodule

### Symptoms/Presentations

- Neck swelling/mass
- Pain or discomfort
- Local pressure symptoms/voice changes
- Thyroid dysfunction
- Incidental or unrelated findings on:
    - Physical examination
    - Imaging


## Investigations

- Blood tests: TSH + free T4
- Ultrasound
- FNAC (+ molecular testing)
- ESR, thyroid antibodies, calcitonin, genetic testing (as indicated)
- Imaging: radioisotope scan, CT scan/MRI, PET scan (as indicated)
- Endoscopy (as indicated)
- Thyroidectomy: diagnostic + therapeutic


## Investigation: Ultrasonography (USG)

- B-mode real-time
- Non-invasive, no radiation, convenient, and inexpensive
- High sensitivity but relatively low specificity
- Role:
    - Extend physical examination
    - Select nodules for FNAC
    - Guide needle aspiration
    - Evaluation of all patients with goiter/palpable nodule
    - **Not** recommended as a screening test


## Thyroid Nodule

### USG Assessment

> Haugen BR, et al. Thyroid 2016
> Thyroid Imaging Reporting and Data Systems (TIRADS)


## Thyroid Nodule

### Fine Needle Aspiration Cytology (FNAC)

| Diagnostic Category        | Risk of Malignancy | Usual Management      |
|----------------------------|--------------------|-----------------------|
| I. Non-diagnostic          | 1-4%               | Repeat FNA            |
| II. Benign                 | 0-3%               | Clinical follow-up    |
| III. AUS or FLUS          | 5-15%              | Repeat FNA            |
| IV. Follicular neoplasm   | 15-30%             | Surgical lobectomy    |
| V. Suspicious of malignancy | 60-75%             | Surgical lobectomy (FS) + TT |
| VI. Malignant              | 97-99%             | Total thyroidectomy (TT) |

AUS: atypia of undetermined significance
FLUS: follicular lesion of undetermined significance

> Bethesda classification


## FNA: Molecular Testing

- Somatic mutations
- BRAF: 40-64%
- Panel of mutations (Asuragen miRInform™): 63-80%
    - Not sensitive but specific: high PPV (rule-in test)
- Gene expression evaluation and miRNA classifier
- ThyroSeq v3 multigene genomic classifier (DNA-RNA)
- Afirma® genomic sequencing classifier (RNA)
    - Highly sensitive but not specific with high NPV (rule-out test)
- For indeterminate (CAT III-IV: FLUS/FN) nodule
- Avoid diagnostic thyroidectomy in 50%

> Alexander EK, New Engl J Med 2012; Haugen BR, et al. Thyroid, 2015; Livhit MJ, et al. JCEM 2018; San Martin VT, et al. JCEM 2019; Endo M, et al. Thyroid 2019; Stewart DL, et al. JAMA Oncol 2019; Grani-G, et al JCEM 2020; Livhit MJ, et al. JAMA Oncol 2021



## ATA Guidelines: Management of Thyroid Nodule

> Haugen BR, et al. Thyroid 2016


## Other Investigations: Imaging and Endoscopy

- **Radio-isotope scintigraphy (I<sup>123</sup> or Tc<sup>99m</sup>):**
    - Diagnosis of malignancy: low sensitivity and specificity
    - Functional assessment in thyrotoxic patients (Graves’ disease, Toxic adenoma, Cold nodule, Toxic nodular goiter)
- **CXR (thoracic inlet)**
- **CT scan/MRI**
- **PET scan**
- **Endoscopy**


## Benign Thyroid Nodules

### Indications of Treatment

- Symptomatic (size of goiter/nodule)
- Increase in goiter size
- Trachea compression or deviation
- Retrosternal extension
- Suspected malignancy
- Cosmetic considerations/patient wish


## Benign Thyroid Nodules

### Surgical Treatment

- **Unilateral lobectomy (hemithyroidectomy):**
    - For uninodular goiter
    - Safe, minimal morbidities, diagnosis and cure
    - Future reoperation on contralateral lobe without difficulty
    - Around 10-20% chance of hypothyroidism
- **Total/near-total thyroidectomy (bilateral thyroidectomy):**
    - For symptomatic multinodular goiter
    - No recurrence/need for reoperation
    - Additional surgical risk (hypoparathyroidism)
    - Needs long-term thyroxine replacement
- **Partial or bilateral subtotal thyroidectomy:**
    - Rarely indicated


## Thyroid Nodule

### Nonsurgical Ablative Treatment

- Ethanol injection (PEI)
- High-intensity focused ultrasound (HIFU)
- Radiofrequency ablation (RFA)
- Percutaneous laser ablation (LA)
- Microwave ablation (MWA)

> Thermal coagulation necrosis
> Cytoplasmic protein dehydration/coagulation necrosis
> Cystic/predominantly cystic, Complex, or solid nodule
> Under LA or sedation
> Clinic or day procedure

> Grani-G, et al. JCEM 2020


## Thyroid Nodule

### Nonsurgical Ablative Treatment

- Volume reduction rate (VRR: 50-80%)
- Patient selection:
    - Symptomatic/single/hyperfunctioning nodule
    - < 4 cm or 20 mL/growth in sonogram
    - Benign (FNAC x2)
    - Motivated patients
- Expectations: preserve function, minimally invasive, avoiding general anesthesia, day procedure, scarless, cosmetic outcome
- Limitations: not curative, unsatisfactory shrinkage, regrowth, additional procedure, risk unique to ablation, expense


## Thyroid Carcinoma

### Major Histologic Types

- Well-differentiated (90%):
    - Papillary (90%)
    - Follicular (10%)
- Poorly differentiated (insular) (<5%)
- Undifferentiated (anaplastic) (<5%)
- Medullary carcinoma (<5%)
- Others (1%): lymphoma, squamous cell carcinoma, sarcoma, metastasis


## Well-Differentiated Thyroid Carcinoma

### Management Considerations

- Extent of thyroidectomy:
    - Hemithyroidectomy vs. total (bilateral) thyroidectomy
- Nature/aim and extent of lymph node/neck dissection:
    - Prophylactic or therapeutic
    - Central and/or lateral compartments
- Postoperative adjuvant therapies:
    - Radioiodine (I<sup>131</sup>) ablation
    - External beam irradiation
    - Thyroxine (T<sub>4</sub>) suppressive therapy


## Well-Differentiated Thyroid Carcinoma

### Risk Groups

|                        | Low Risk | High Risk |
|------------------------|----------|-----------|
| % of patients         | 85-90%   | 10-15%    |
| Mortality (10-20 yrs) | 2-5%     | 40-50%   |
| Recurrence            | 10%      | 45%      |


## Papillary Thyroid Carcinoma (PTC)

### Management Controversy for Low-Risk Patients

- Early stage: < 4 cm, no invasion, no LN metastasis
- Majority as papillary microcarcinomas (PTMC): < 1 cm
- Survival: nearly 100%
- Overtreatment/surgical risk vs. avoid recurrence/facilitate follow-up
- Patient's vs. physician's preference
- Personalized treatment

| Total Thyroidectomy                                      | Hemithyroidectomy                                     |
|----------------------------------------------------------|---------------------------------------------------------|
| Commonly multifocal and bilateral                      | Excellent survival and low recurrence                   |
| Allows RAI ablation and thyroglobulin (Tg) monitoring | Avoid T<sub>4</sub> replacement                         |
|                                                         | Lower morbidity rate by experienced surgeons           |



## Cervical Lymph Nodes in PTC

### Management

- **Central (level VI: pre- and para-tracheal):** same incision
    - Prophylactic/routine vs. therapeutic
    - Reduction in disease recurrence/reoperations
    - Upstaging disease and increased use of I<sup>131</sup>
    - Increased morbidity: hypoparathyroidism
- **Lateral (level II-V):** extended incision
    - Usually therapeutic
    - Clinically involved or FNAC proven nodes
    - Excisional (Berry-picking)
    - Modified/functional/selective neck dissection


## Adjuvant Therapy: Use of Radioiodine (I<sup>131</sup>) Ablation

- Follows total/near-total thyroidectomy
- Thyroxine withdrawal vs. thyrogen (recombinant TSH)
- Therapy: high risk (stage III/IV disease)
    - Gross persistent/residual disease
    - Nodal or distant metastases
- Ablation: low-risk (selected stage I and stage II)
    - Destroy occult microscopic foci
    - Facilitate disease surveillance
    - Low dose (30 mCi) as effective as higher dose (100 mCi)
    - Short and long-term adverse effects

> Schlumberger M, et al. New Engl J Med 2012


## Papillary Thyroid Microcarcinoma (PTMC)

### Definition and Relevance

- WHO: < 1 cm + detected incidentally
- AJCC pTNM staging:
    - < 1 cm
    - Majority pT1a or stage I disease
    - Usually incidentally detected
- Low-risk or extremely low-risk
- Excellent or almost 100% survival
- Less aggressive treatment (lobectomy) or active observation


## PTMC: Active Observation

- Biopsy-proven incidental PTMC
- No metastases/invasion/high-grade subtype
- Tumor progression (up to 20 years):
    - Increased size (≥ 3 mm): 8%
    - Novel nodal metastases: 3.5%
- Surgical treatment for tumor progression
- Feasible treatment option

> Choi YS, et al Thyroid 2020; Cho, SJ, et al Thyroid 2020; Yan L, et al. Thyroid 2021

### Thermal Ablation

> Ito Y & Miyauchi A. Thyroid 2003; JCEM 2007; World J Surg 2010; Curr Opin Oncol 2015; Sugitani I al World J Surg 2010; Miyauchi A. World J Surg 2016; Thyroid 2017; Morinelo E, et al JCEM 2019

- Meta-analysis and propensity matched analysis
- Complete ablation/volume reduction/safety
- Tumor progression, recurrence, nodal metastasis same
- Possibly another alternative for PTMC without metastasis


## Thyroid Carcinoma: Medullary Thyroid Carcinoma (MTC)

- Calcitonin (basal/stimulated) as marker
- Total thyroidectomy
- Central + lateral neck dissection
- Familial cases (1/3):
    - MEN IIA
    - MEN IIB
    - Familial MTC
- Genetic analysis: RET proto-oncogene
- Prophylactic thyroidectomy (5-10 yrs)


## Thyroid Carcinoma: Anaplastic Carcinoma

- Elderly with poor co-morbid state
- Aggressive and rapidly growing
- Locally advanced disease
- Frequent distant metastases
- Lack of effective treatment
- Chemoirradiation + resection + targeted therapy
- Invariably palliative and fatal
          </div>
        </body>
      </html>
    